PERTH, Australia – Melbourne-based regenerative medicine company Cynata Therapeutics Ltd. is gearing up to take its Cymerus mesenchymal stem cell (MSC) product candidate CYP-001 into phase II trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback